Drug intelligence / Profile preview

CX501

Development stage: Phase 2
Lead developer: Takeda
Modality: Cell Therapies
Administration: Topical, Implant

Overview

CX501 is a tissue-engineered cultured chimeric skin product developed by TiGenix (formerly Cellerix) for the treatment of skin lesions associated with Epidermolysis Bullosa (EB). The therapy consists of a bilayered structure containing allogeneic human keratinocytes and fibroblasts, typically sourced from neonatal foreskin, which are seeded onto a fibrin-based scaffold. CX501 is designed to function as a biological dressing or skin substitute that promotes wound healing by providing structural proteins and secreting essential growth factors and cytokines. This helps to stabilize the dermal-epidermal junction and accelerate re-epithelialization in patients who suffer from chronic, non-healing wounds due to genetic deficiencies in skin adhesion proteins.

Other names: CX501CX-501CX 501Cultured chimeric skin

Beyond the preview

Go deeper on CX501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX501.

Explore the full profile